Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

Share Price is delayed by 15 minutes
Get Live Data
8.30    -0.15 (-1.78%)
Bid:
8.00
Ask:
8.60
Spread: 0.60 (7.50%)
Market Cap: £18.17m
IXI Live PriceLast checked at - London Stock Exchange

Intraday Ixico Share Chart

Director/PDMR Shareholding

31 Dec 2009 09:26

RNS Number : 8806E
Phytopharm PLC
31 December 2009
Β 

ο»Ώ

NOTIFICATION OF TRANSACTIONS OF DIRECTORS, PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY OR CONNECTED PERSONS

This form is intended for use by anΒ issuerΒ to make aΒ RISΒ notification required byΒ DRΒ 3.1.4R(1).

Β 

(1)

AnΒ issuerΒ making a notification in respect of a transaction relating to theΒ sharesΒ or debentures of theΒ issuerΒ should complete boxes 1 to 16, 23 and 24.

(2)

AnΒ issuerΒ making a notification in respect of a derivative relatingΒ toΒ theΒ sharesΒ of theΒ issuerΒ should complete boxes 1 to 4, 6, 8,Β 13, 14, 16, 23 and 24.Β 

(3)

AnΒ issuerΒ making a notification in respect of options granted to aΒ director/person discharging managerial responsibilitiesΒ should complete boxes 1 to 3 and 17 to 24.Β 

(4)

AnΒ issuerΒ making a notification in respect of aΒ financial instrumentΒ relating to theΒ sharesΒ of theΒ issuerΒ (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.Β 

Β 

Please complete all relevant boxes in block capital letters.

1.Β Name of theΒ issuer

PHYTOPHARM PLC

2.Β State whether the notification relates to (i) a transaction notified in accordance withΒ DRΒ 3.1.4R(1)(a); orΒ (ii)Β DRΒ 3.1.4(R)(1)(b) a disclosure made in accordance with section 324 (as extended by section 328) of the Companies Act 1985; or (iii) both (i) and (ii)

(III) BOTHΒ (I)Β AND (II)

3.Β Name ofΒ person discharging managerial responsibilities/director

DR PETER ROBIN BLOWER, NON-EXECUTIVE DIRECTOR

4.Β State whether notification relates to aΒ personΒ connected with aΒ person discharging managerial responsibilities/directorΒ named in 3 and identify theΒ connected person

AS 3 ABOVE

5.Β Indicate whether the notification is in respect of a holding of theΒ personΒ referred to in 3 or 4 above or in respect of a non-beneficial interest

AS 3 ABOVE

6.Β Description ofΒ sharesΒ (includingΒ class), debentures or derivatives or financial instruments relating toΒ shares

ORDINARY SHARES OF 1 PENCE EACH

7.Β Name of registered shareholders(s) and, if more than one, the number ofΒ sharesΒ held by each of them

AS 3 ABOVE

8Β State the nature of the transaction

SHARES ACQUIRED

9.Β Number ofΒ shares, debentures or financial instruments relating toΒ sharesΒ acquired

75,000

10.Β Percentage of issuedΒ classΒ acquired (treasury sharesΒ of thatΒ classΒ should not be taken into account when calculating percentage)

0.02%

11.Β Number ofΒ shares, debentures or financial instruments relating toΒ sharesΒ disposed

12.Β Percentage of issuedΒ classΒ disposed (treasury sharesΒ of thatΒ classΒ should not be taken into account when calculating percentage)Β 

13.Β Price perΒ shareΒ or value of transaction

10Β PENCE PER SHARE

14.Β Date and place of transaction

29Β DecemberΒ 2009, LONDON

15.Β Total holding following notification and total percentage holding following notification (anyΒ treasury sharesΒ should not be taken into account when calculating percentage)

193,682 - 0.06%

16.Β Date issuer informed of transaction

30 DECEMBER2009

If aΒ person discharging managerial responsibilitiesΒ has been granted options by theΒ issuerΒ complete the following boxes

17Β Date of grant

18.Β Period during which or date on which it can be exercised

19.Β Total amount paid (if any) for grant of the option

20.Β Description ofΒ sharesΒ or debentures involved (classΒ and number)

21.Β Exercise price (if fixed at time of grant) or indication that price is to be fixed at the time of exercise

22.Β Total number ofΒ sharesΒ or debentures over which options held following notification

23.Β Any additional information

24.Β Name of contact and telephone number for queries

ZOE MCGOWAN 01480 437697

Name and signature of duly authorised officer ofΒ issuerΒ responsible for making notification

ZOE MCGOWAN

Date of notification

31Β DECEMBERΒ 2009

ENDΒ 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
RDSTBBLTMMTJMJL
Date   Source Headline
7th Feb 20237:00 amRNSTrading Update
31st Jan 20234:35 pmRNSPrice Monitoring Extension
31st Jan 20232:05 pmRNSSecond Price Monitoring Extn
31st Jan 20232:00 pmRNSPrice Monitoring Extension
31st Jan 202311:05 amRNSSecond Price Monitoring Extn
31st Jan 202311:00 amRNSPrice Monitoring Extension
27th Jan 20231:00 pmRNSResult of AGM
3rd Jan 20237:00 amRNSTotal Voting Rights
22nd Dec 202212:18 pmRNSDirector Bed & ISA Dealing
13th Dec 20227:00 amRNSPDMR Exercise of Options
9th Dec 20229:05 amRNSContract Win
8th Dec 20223:34 pmRNSContract Update
7th Dec 20227:00 amRNSFinancial Results for the year ended 30 Sept 2022
21st Nov 20227:00 amRNSNotice of Results and Investor Presentation
25th Oct 20227:00 amRNSTrading Update
21st Sep 202210:35 amRNSHD-IH Consortium
14th Sep 20227:00 amRNSGrant of Share Options
1st Sep 20227:00 amRNSTrading Update and FY2023 Guidance
4th Aug 20227:00 amRNSContract Win
26th Jul 202211:22 amRNSContract Win - Replacement
21st Jul 20227:00 amRNSContract Win
14th Jun 20227:00 amRNSContract Extension
24th May 20227:00 amRNSHalf-year Report and Trading Update
16th May 20227:00 amRNSInvestor Presentation
10th May 20227:00 amRNSConsortium Agreement in Huntington's Disease
25th Apr 20227:00 amRNSTrading Update
21st Apr 20227:00 amRNSNew Contract Win
8th Mar 20227:00 amRNSContract worth circa £800k
14th Feb 20227:00 amRNSLaunch of IXIQ.Ai Deep learning AI-based platform
8th Feb 202212:30 pmRNSHolding(s) in Company
8th Feb 20227:00 amRNSContract award worth circa £1.0m
31st Jan 20227:00 amRNSAppointment of Senior Therapeutic Advisor
26th Jan 20227:00 amRNSDementia collaboration
21st Jan 20227:00 amRNSNon-Executive Director Appointment
20th Jan 202210:50 amRNSResult of AGM
20th Jan 20227:00 amRNSHuntington’s disease contract update
10th Jan 20227:00 amRNSGrant of share options
7th Dec 20217:00 amRNSFinancial Results for the year ended 30 Sept 2021
22nd Nov 20217:00 amRNSNotice of Results
1st Nov 20216:08 pmRNSHolding(s) in Company
1st Nov 20217:00 amRNSNew contract worth >£1.0m
20th Oct 20214:27 pmRNSContract update
18th Oct 20217:00 amRNSTrading Update for year ended 30 September 2021
22nd Sep 20217:00 amRNSNew contract worth >$750k
20th Sep 20217:00 amRNSPhase II HD contract with new client worth >$500K
8th Sep 20217:00 amRNSPhase I MSA contract award worth >$500k
6th Aug 20217:00 amRNSTrading Update
23rd Jun 20213:32 pmRNSIssue of Equity
21st Jun 20212:31 pmRNSHolding(s) in Company
15th Jun 20217:00 amRNSFurther investment in Ixico plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.